4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
4D Molecular Therapeutics laid off a quarter of its workforce last month with early-stage R&D bearing the brunt of the changes. The genetic medicines biotech said shrinking its headcount by 25% should ...
NEW YORK — Beneath a liberated Manhattan sky, Adidas clasped to the role of Dr. Frankenstein. Its mission was simple: to further innovate and push the limits of athletic footwear. In partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback